However, CX3CL1-expressing MDA-MB-453 HTM treated with trastuzumab showed a slightly enhanced inhibition of tumor growth indicated by an enhanced significance between control and trastuzumab treated HTM (MDA-MB-453empty p = 0.0201versus MDA-MB-453CX3CL1 p > 0.0001) and a significantly reduced formation of lung metastases. Here, CX3CL1 is linked to neoplasm.